What have multicentre registries across the world taught us about the disease features of systemic sclerosis?

Abstract

Introduction

The aim of this study is to compare the clinical features, mortality and causes of death of systemic sclerosis (SSc) patients in four large multicentre registries.

Methods

Patients seen at least once in the Australian Scleroderma Cohort Study (ASCS) (n = 1714), the Canadian Scleroderma Research Group (CSRG) (n = 1628), the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR) Network (n = 13,996) and the Systemic Sclerosis Cohort in Singapore (SCORE) (n = 500) before August 2016 were included. Clinical manifestations and survival in cohorts and disease subtypes were compared.

Results

Among 17,838 SSc patients, most were female (86.1%), Caucasian (84.6%) and had the limited cutaneous subtype (lcSSc) (65.0%). The anti-centromere autoantibody was the most prevalent (37.6%). More patients in SCORE had the diffuse subtype (dcSSc) (49.3%) and Scl-70 autoantibody (38.8%) (p<0.001). Patients with dcSSc were more likely to be younger and male (p<0.001) and have shorter disease duration, more calcinosis, tendon friction rubs and synovitis (all p<0.001). Interstitial lung disease (ILD) occurred more frequently in dcSSc but prevalence of pulmonary arterial hypertension (PAH) was similar in both subtypes. More deaths occurred among SCORE patients who had the shortest median survival (p<0.001). The survival of patients with early disease, males and those with dcSSc was shorter than that of patients with prevalent disease, female gender and lcSSc, respectively. SSc-related complications accounted for more than 50% of deaths, with PAH and ILD being the most common.

Conclusions

This meta-cohort of SSc patients, the largest reported to date, provides insights into the impact of race and sex on disease manifestations and survival and confirms the early mortality in this disease.

Keywords

Clinical features Cohort study Multicentre registries Survival Systemic sclerosis

Get full access to this article

View all access options for this article.

References

Denton

Systemic sclerosis: from pathogenesis to targeted therapy.

Clin Exp Rheumatol 2015;33(4)(Suppl 92):S3S7

Thombs

Taillefer

Hudson

Baron

Depression in patients with systemic sclerosis: a systematic review of the evidence.

Arthritis Rheum 2007;57(6):10891097

Hao

Hudson

Baron

et al.

Early mortality in a multinational systemic sclerosis inception cohort.

Arthritis Rheumatol 2017;69(5):10671077

LeRoy

Black

Fleischmajer

et al.

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

J Rheumatol 1988;15(2):202205

Bacher

Mittoo

Hudson

et al.

Canadian Scleroderma Research Group.

Systemic sclerosis in Canadas North American Native population: assessment of clinical and serological manifestations. J Rheumatol 2013;40(7):11211126

Chifflot

Fautrel

Sordet

Chatelus

Sibilia

Incidence and prevalence of systemic sclerosis: a systematic literature review.

Semin Arthritis Rheum 2008;37(4):223235

Masi

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Arthritis Rheum 1980;23(5):581590

van den Hoogen

Khanna

Fransen

et al.

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Arthritis Rheum 2013;65(11):27372747

Nikpour

Hissaria

Byron

et al.

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

Arthritis Res Ther 2011;13(6):R211

10.

Thombs

Hudson

Bassel

Taillefer

Baron

Canadian Scleroderma Research Group. Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients.

Arthritis Rheum 2009;61(7):966973

11.

Tyndall

Mueller-Ladner

Matucci-Cerinic

Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database.

Ann Rheum Dis 2005;64(7):1107

12.

Müller-Ladner

Tyndall

Czirjak

Denton

Matucci-Cerinic

EUSTAR centres.

Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73(2):324327

13.

Santosa

Tan

Teng

et al.

Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort.

Scand J Rheumatol 2016;45(6):499506

14.

Singapore Department of Statistics. Census of Population 2010 Advance Census release.

2010 Available from: http://www.singstat.gov.sg/statistics/browse-by-theme/population-and-population-structure. Accessed August 16, 2017.

15.

Steele

Hudson

Baron

Canadian Scleroderma Research Group.

Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64(4):519524

16.

Galiè

Humbert

Vachiery

et al.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Eur Heart J 2016;37(1):67119

17.

Traub

Shapiro

Rodnan

et al.

Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis.

Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983;62(6):335352

18.

Steen

Medsger

Changes in causes of death in systemic sclerosis, 19722002.

Ann Rheum Dis 2007;66(7):940944

19.

Mayes

Giannini

Pachman

Buyon

Fleckman

Connective tissue disease registries.

Arthritis Rheum 1997;40(9):15561559

20.

Galluccio

Walker

Nihtyanova

et al.

Registries in systemic sclerosis: a worldwide experience.

Rheumatology (Oxford) 2011;50(1):6068

21.

Simeón-Aznar

Fonollosa-Plá

Tolosa-Vilella

et al.

Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.

Semin Arthritis Rheum 2012;41(6):789800

22.

Wang

Assassi

Guo

et al.

Clinical and serological features of systemic sclerosis in a Chinese cohort.

Clin Rheumatol 2013;32(5):617621

23.

Gelber

Manno

Shah

et al.

Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

Medicine (Baltimore) 2013;92(4):191205

24.

Laing

Gillespie

Toth

et al.

Racial differences in scleroderma among women in Michigan.

Arthritis Rheum 1997;40(4):734742

25.

Allanore

Limited cutaneous systemic sclerosis: the unfairly neglected subset.

J Scleroderma Relat Disord 2016;1(3):241246

26.

Steen

Powell

Medsger

Jr.

Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Arthritis Rheum 1988;31(2):196203

27.

Meyer

De Chaisemartin

Nicaise-Roland

et al.

Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study.

J Rheumatol 2010;37(1):125130

28.

Hamaguchi

Hasegawa

Fujimoto

et al.

The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.

Br J Dermatol 2008;158(3):487495

29.

Meyer

Fertig

Lucas

Somogyi

Medsger

Jr.

Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.

J Rheumatol 2007;34(1):104109

30.

Bunn

Denton

Shi-Wen

Knight

Black

Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.

Br J Rheumatol 1998;37(1):1520

31.

Khimdas

Harding

Bonner

Zummer

Baron

Pope

Canadian Scleroderma Research Group.

Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res (Hoboken) 2011;63(1):142149

32.

Tiev

Diot

Clerson

et al.

Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie).

J Rheumatol 2009;36(7):14701476

33.

Avouac

Airò

Meune

et al.

Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies.

J Rheumatol 2010;37(11):22908

34.

Iudici

Fasano

Iacono

Russo

Cuomo

Valentini

Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Clin Rheumatol 2014;33(2):153164

35.

Meier

Frommer

Dinser

et al.

EUSTAR Co-authors.

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71(8):13551360

36.

Fransen

Popa-Diaconu

Hesselstrand

et al.

Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres.

Ann Rheum Dis 2011;70(10):17881792

37.

Elhai

Avouac

Walker

et al.

EUSTAR co-authors.

A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016;75(1):163169

38.

Strickland

Pauling

Cavill

Shaddick

McHugh

Mortality in systemic sclerosis-a single centre study from the UK.

Clin Rheumatol 2013;32(10):15331539

39.

Kuo

See

et al.

Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan.

Scand J Rheumatol 2011;40(5):373378

40.

Walker

Tyndall

Czirják

et al.

EUSTAR co-authors.

Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009;68(6):856862

41.

Andréasson

Saxne

Bergknut

Hesselstrand

Englund

Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria.

Ann Rheum Dis 2014;73(10):17881792

42.

Foocharoen

Yenrom

Mahakkanukrauh

Suwannaroj

Nanagara

Prevalence and causes of loss to follow-up among patients with systemic sclerosis.

J Clin Rheumatol 2014;20(8):456